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ABSTRACT
Re-consent in research, the asking for a new consent if there is a change
in protocol or to confirm the expectations of participants in case of change,
is an under-explored issue. There is little clarity as to what changes should
trigger re-consent and what impact a re-consent exercise has on partici-
pants and the research project. This article examines applicable policy
statements and literature for the prevailing arguments for and against
re-consent in relation to longitudinal cohort studies, tissue banks and
biobanks. Examples of re-consent exercises are presented, triggers and
non-triggers for re-consent discussed and the conflicting attitudes of com-
mentators, participants and researchers highlighted. We acknowledge
current practice and argue for a greater emphasis on ‘responsive
autonomy,’ that goes beyond a one-time consent and encourages greater
communication between the parties involved. A balance is needed between
respecting participants’ wishes on how they want their data and samples
used and enabling effective research to proceed.
INTRODUCTION
The phrase, ‘plus ça change, plus c’est la même chose’ –
loosely translated as ‘the more things change, the more
they stay the same’1 – is particularly true when looking at
the need to balance the autonomy of participants, as
expressed through their consent to participate in bio-
medical research, with the fast pace of scientific enquiry.
Consent, as it relates to longitudinal biomedical research
has always been contentious. As these projects mature
and the pressure increases at national and international
levels to link resources to facilitate access and data
sharing,2 there is a need to ensure that consent is valid
and appropriate at every stage of the process and with
respect to future possibilities.
Because longitudinal projects follow participants over
time and provide access to resources for many years,
change is inevitable. The objectives and science of the
project, and the views of participants, may change. New
uses of existing data may arise. All of these may cause
projects to consider moving outside the scope of the origi-
nal consent. Currently longitudinal projects generally use
‘broad’ consent for future unspecified research with
appropriate governance mechanisms, a paradigm that is
designed to be flexible and responsive. Consent should be
an ongoing process that allows the research and the
expectations of participants to move together. However,
broad consent is not a complete answer, relying on gov-
ernance mechanisms to decide on the acceptability of new
propositions for study resources. At some tipping point,
re-consent needs to be an option in order to allow indi-
viduals to make their own decisions about participation.
METHODOLOGY
The debates have so far mainly unfolded around the
nature and potential applications of broad consent,
and re-consent has been underexplored. We conducted
1 B.A. Karr. Epigram. Les Guêpes. 1849.
2 European Science Foundation. 2007. Shared Responsibilities in
Sharing Research Data: Policies and Partnerships. Available at: http://
www.esf.org/fileadmin/Public_documents/Publications/
SharingData_01.pdf [Cited 2014 May 10].
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a systematic review of applicable policy statements and
literature for the arguments for and against re-consent
from the perspective of longitudinal cohort studies, tissue
banks and biobanks (hereafter ‘projects’). The following
databases were searched: Web of Knowledge, Scopus,
PubMed, the British Library Catalogue, Google Scholar,
PMC, OpenGrey, official-documents.gov.uk, Papers-
First, WorldCat and WorldCatDissertations. The search
terms selected were: reconsent* OR re-consent* AND
research AND participant*. Searches using these terms
were conducted between January 23 and February 5, 2013.
Where possible, depending on the databases’ search
engines, the results returned were limited to display only
results from 1990 onwards, as we judged re-consent in this
context to be a relatively recent activity. Results were
reviewed for inclusion based on our research questions:
What are seen as the benefits and disadvantages to
re-consent? What do people feel should and should not
trigger re-consent? What circumstances actually trigger a
re-consent exercise and what is the outcome? After review-
ing our results we concluded that there was insufficient
empirical data to present a systematic analysis. In addi-
tion, although there is considerable opinion on re-consent,
there were an insufficient number of comparable studies to
allow us to draw supportable conclusions. Therefore a less
constrained review is reported here, presenting the issues
and identifying gaps in the research.
No agreed definition of re-consent exists and there is
considerable ambiguity in how it is described and used in
practice. Re-consent has been used to describe activities
ranging from repeating the consent process, where refusal
requires a participant to withdraw completely from the
project, to asking for consent for a single new aspect of
the project, refusal of which would allow continued par-
ticipation. As we found insufficient evidence available to
individually analyse each of these, for this article we
define re-consent broadly as the process of seeking par-
ticipant consent to change or update their existing
consent to allow their samples and data to be used in a
different way from that which was originally agreed3 or to
confirm that new uses fall within the expectations and
understandings of participants. We have excluded
re-contact for administrative purposes that is agreed in
the original consent, re-consent in paediatric studies
when a child comes of age, and in clinical trials when new
information arises (e.g. drug safety) that may change the
conduct of the trial or influence a participant’s decision to
participate. We present examples of re-consent exercises,
discuss triggers and non-triggers for re-consent and
highlight the conflicting attitudes of commentators (i.e.
academic and clinical professionals who have published
the issues), participants and researchers. Finally, we
argue for other alternatives, such as a greater emphasis
on ‘responsive autonomy’, that go beyond one-time
consent and encourage greater communication between
the parties involved in both directions.
RESULTS
Current policy on re-consent
Internationally, guidance from policy bodies is vague,
focusing on re-consent to ensure that a participant’s
consent remains informed if there are changes in the pro-
tocol or in the circumstances of the participant. For
example, the Canadian Tri-Council Policy Statement
declares: ‘the researcher has an on-going ethical and legal
obligation to bring to participants’ attention any changes
to the research project that may affect them.’4 Similarly,
the Council for International Organizations of Medical
Sciences (CIOMS) notes, ‘[w]hen material changes occur
in the conditions or the procedures of a study, and also
periodically in long-term studies, the investigator should
once again seek informed consent from the subjects.’5 The
US Office Human Research Protection suggests that
consent may need to be ‘repeated’ or ‘supplemented’ if
the protocol design or risks have changed or if a substan-
tial period of time has elapsed since the original consent.6
Questions about length of time elapsed between consent
and use of data is particularly pertinent for longitudinal
research, but high-level policy statements give little spe-
cific guidance on procedure. The Organization for Eco-
nomic Co-operation and Development (OECD) in its
guidance for biobanks states that review practices, in
accordance with applicable law and oversight mecha-
nisms, should be in place ‘where human biological mate-
rials or data are to be used in a manner not anticipated in
the original informed consent process.’7
There is little clarity regarding any legal requirements
for re-consent. At a European level, the Council of
Europe (CoE) Additional Protocol to the Convention on
Human Rights and Biomedicine, concerning Biomedical
3 E.J. Ludman, S.M. Fullerton, L. Spangler, S.B. Trinidad, M.M. Fujii,
G.P. Jarvik, et al. Glad you Asked: Participants’ Opinions of
Re-consent for Dbgap Data Submission. J Empir Res Hum Res Ethics
2010; 5: 9–16, p.12.
4 Canadian Institutes of Health Research, Natural Sciences and
Engineering Research Council of Canada, and Social Sciences and
Humanities Research Council of Canada. Tri-Council Policy Statement
– Ethical Conduct for Research Involving Humans. 2010, p.33–34.
5 Council for International Organizations of Medical Science. Interna-
tional ethical guidelines for biomedical research involving human sub-
jects. Available at http://www.cioms.ch/publications/layout_guide2002
.pdf [Accessed 20 November 2014].
6 Office for Human Research Protections. Informed Consent. Available
at: http://www.hhs.gov/ohrp/policy/consentckls.html [Accessed 10 May
2014].
7 Organization for Economic Cooperation Development. OECD
Guidelines on Human Biobanks and Genetic Research Databases. Eur
J Health Law 2010; 17: 191–204, p.198.
Susan Wallace, Elli Gourna, Graeme Laurie, Osama Shoush and Jessica Wright2
© 2015 The Authors. Bioethics published by John Wiley & Sons Ltd
Respecting Autonomy Over Time 211
VC 2015 The Authors. Bioethics published by John Wiley & Sons Ltd
Research8 emphasizes that in case of new developments
(i.e. additional scientific information becoming available
regarding the research or changes in implications for par-
ticipants), additional consent might be required. This
protocol was, as of November 2014, signed by 22 member
States, but only ratified by nine, with ratification neces-
sary for integration into national legislation. The CoE
previously published a recommendation (Rec(2006)4)9
suggesting that if the scope of the research is altered new
consent should be sought. This is not legally binding and
is currently under review, in the light of scientific devel-
opments and governance experiences.
Individual nation states offer little legal guidance and
existing laws are not explicit. Laws in France and Italy10
state that re-consent would be desirable if changes are
made to the original research, but if this is judged to be
impossible an authorization from the relevant authority
should be sought. Similarly, in the US all research funded
at any institution receiving federal funding has to abide
by section 45 CFR 46.116(d) of the Code of Federal
Regulations regarding ‘Protection of Human Subjects’11
which states that institutional review boards (IRBs) are
responsible for deciding when re-consent is required.
Initiatives, such as the Global Alliance for Genomics
and Health, actively promote broad consent as a way to
encourage sharing of results from research studies.12
Research funders have long supported sharing biomedi-
cal data but recognise that flexibility is needed as there are
a ‘wide range of attitudes towards giving consent over
time and for different research purposes’.13
Current positions supporting or
opposing re-consent
Arguments around re-consent are linked to discussions
about informed consent more generally; specifically that
consent at a single time-point is inadequate for longitu-
dinal projects because an individual cannot agree to
future unknown uses of samples and data, and therefore
consent is not informed throughout participation.14
Consent should not be seen as a ‘snapshot’ captured in a
legal document, but as ‘the starting point of a relation-
ship that will evolve over time’.15
Arguments in favour of re-consent emphasize indi-
vidual decision-making. Seeking re-consent when the
reach of the original consent is in doubt gives participants
greater autonomy and control over their samples and
data16 and is thought to increase public trust in genomics
research.17 Studies examining public viewpoints suggest
that being asked for consent for each research use would
enhance feelings of control, trust in the study, and would
foster respect.18 Consent for specific uses could prevent
misuse of resources, such as allowing research participants
to refuse the use of their data in studies that may go against
religious or moral beliefs.19 A strong relationship and
frequent interaction between longitudinal research pro-
jects and participants is seen as beneficial for the project,
fostering better relationships and increasing participant
engagement.20 This allows participants to make autono-
mous decisions, including the right to withdraw, which is
generally seen as absolute (subject to practical considera-
tions when research resources have already been used up
or transferred).
Arguments against re-consent focus on disadvantages
for the project, as well as for the participant. For the
project, they centre on the impracticalities of the
re-consenting process, the high cost in terms of time and
resources of finding and re-consenting research partici-
pants21 and the reduction in the cohort size over time,
8 Council of Europe. Additional Protocol to the Convention on
Human Rights and Biomedicine, concerning Biomedical Research.
2005 Available at: http://conventions.coe.int/Treaty/en/Treaties/Html/
195.htm [Accessed 24 November 2014].
9 Council of Europe. Recommendation 4 on Research on Biological
Materials of Human Origin. 2006.
10 Republique Francaise. Code De La Santé Publique – Loi du Aout
2004. 2004; Gazzetta Ufficiale n. 52 del 2-3-2012. Available at: http://
www.altalex.com/index.php?idnot=17432 [Cited 2014 January 29].
11 Department of Health and Human Services, Federal Policy for the
Protection of Human Subjects (‘Common Rule’), 45 CFR 46.116(d).
2009 Available at: http://www.hhs.gov/ohrp/humansubjects/
commonrule/ [Cited 2014 May 5].
12 Global Alliance for Genomics and Health. 2014. Available at: http://
www.globalalliancepr.org/ [Cited 2014 June19].
13 Wellcome Trust. Nuffield Council on Bioethics: The Linking and Use
of Biological and Health Data – Response by the Wellcome Trust. 2014,
p.11.
14 M.F.A. Otlowski. Tackling Legal Challenges Posed By Population
Biobanks: Reconceptualising Consent Requirements. Med Law Rev
2012; 20: 191–126.
15 G. Laurie & E. Postan. Rhetoric or Reality: What is the Legal Status
of the Consent Form in Health-Related Research? Med Law Rev 2013;
21: 371–414, p.371–372.
16 B.E. Ellerin, R.J. Schneider, A. Stern, P.G. Toniolo & S.C. Formenti.
Ethical, Legal, and Social Issues Related to Genomics and Cancer
Research: the Impending Crisis. J Am Coll Radiol 2005; 2: 919–926.
17 Otlowski op. cit. note 14; Ellerin et al., op. cit. note 16; Phoebe.
Harmonising Biobank Research: Maximising Value – Maximising Use,
March 2009 Conference Summary. 2009; M.A. Igbe & C.A.
Adebamowo. Qualitative Study of Knowledge and Attitudes to
Biobanking Among Lay Persons in Nigeria. BMCMedical Ethics 2012;
13; A.L. McGuire, T. Caulfield & M.K. Cho, Science and Society –
Research Ethics and the Challenge of Whole-Genome Sequencing.
Nature reviews Genetics 2008; 9: 152–156.
18 J. Murphy, J. Scott, D. Kaufman, G. Geller, L. LeRoy & K. Hudson.
Public Perspectives on Informed Consent for Biobanking. Am J Public
Health 2009; 99: 2128–2134.
19 Ibid.
20 S.B. Trinidad, S.M. Fullerton, E.J. Ludman, G.P. Jarvik, E.B.
Larson & W. Burke. Research ethics. Research Practice and Participant
Preferences: the Growing Gulf. Science 2011; 331: 287–288; V. Árnason.
Scientific citizenship, benefit, and protection in population-based
research. Ethics Res Biob 2009: 131–141.
21 Global Alliance op. cit. note 12; Otlowski op. cit. note 14; Ellerin
et al. op. cit. note 16; T. Caulfield, A.L. McGuire, M. Cho, et al.
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leading to it being more difficult to conduct research.22 Re-
consent could introduce selection bias, as those who agree
could be materially different from those who do not, thus
potentially affecting the scientific validity of the data.23 If
the consent becomes so specific, resulting in it only being
able to be used for certain activities, this could limit the
usefulness of the resource,24 if the original consent was
determinedly broad in nature. One might also argue that
re-consent ‘cheapens’ broad consent, in that it suggests
that existing governance mechanisms are insufficient.
‘Consent fatigue’ is often raised; re-consent procedures
may constitute a nuisance or loss of privacy, and may
cause unnecessary distress for participants.25 Yet there is
ambiguity when this position is explored. When cancer
patients contributing to a tissue banking study were
asked their preferences, ‘58% reported that re-consent
was a waste of time and money but 51.7% indicated they
would feel respected and involved if asked to
re-consent.’26 As expressed by another study, ‘the request
represented a tangible demonstration of the researchers’
trustworthiness and regard.’27 This leads to questions of
how much this reflects the impact of being asked for
re-consent, but also simply being given the opportunity to
express one’s preference. Thus, re-consent is not a black-
and-white process. Perhaps an examination of specific
triggers can assist in determining when re-consent is war-
ranted, both for the participants and for projects.
Triggers for re-consent
Re-consent is seen as not necessary in cases where there
are only minor protocol changes that cause no perceived
increased risk or concern to the participant28 or where the
transaction and economic costs of seeking re-consent
would be disproportionate to the risk to participants or
the project itself. The following changes may require
re-consent: major changes in protocol, researching a new
unrelated condition, adding new genetic element, moving
from phenotype-driven research to whole genome
sequencing (WGS), and ‘controversial’ research. These
events could impact participants, both in terms of their
privacy (re-identification from genetic data) and their
autonomy (new uses without their consent). Change
without re-consent could undermine the trust of partici-
pants and could cause researchers to suffer reputational
damage. If projects, through the new use, discover genetic
information that should be fed back to participants, there
may be an impact on biological relatives and social fami-
lies who have not consented directly to the research.
The longer a project continues the more likely there
will be more significant changes in the protocol moving
outside existing expectations and re-consent may be
needed. The UK Medical Research Council (MRC) Cog-
nitive Function and Ageing Study re-consented their par-
ticipants because it was judged that the original consent
did not adequately explain how samples and data were
being used; this could be seen as increasing the risk to
participants.29 Agreement was obtained from, or on
behalf, of 197 of the 224 respondents (88%) it was possi-
ble to approach.30 Researchers from the UK Interna-
tional Cancer Genome Consortium (ICGC) Prostate
Cancer project successfully re-consented participants to
allow samples and data to be used for ‘disease’ research,
broadened from the original consent limited to ‘cancer’
research. In their report of January 2013, they state that
in one recruitment site, 77 of 79 men approached agreed
to the broader consent, with two men yet to answer. At a
second site, 269 of 313 (86%) men agreed, and 44 (14%)
declined.31 These results show that a strong majority of
participants were happy to consent under these new
terms. Such results can be interpreted as supporting
Steinsbekk’s argument that ‘there is no ethical difference
between research on diabetes, cancer or cardiovascular
disease’ if the research aims fall within the framework or
ethos of the original consent.32 However, this position can
only be supported if more is known about the original
expectations of the participants, how closely the new use
fits within that framework and whether the act of asking
was the driver for agreement as opposed to a lack of
concern about the new use.
Consensus Statement. PLoS Biology 2008; 6: 73; C.A. McCarty, A.
Garber, J.C. Reeser & N.C. Fost. Personalized Med Res P, Ethics
Security Advisory B. Study Newsletters, Community and Ethics Advi-
sory Boards, and Focus Group Discussions Provide Ongoing Feedback
for a Large Biobank. Am J Med Genet A 2011; 155A: 737–741.
22 McCarty et al. op. cit. note 21; O.F. Bathe & A.L. McGuire. The
Ethical Use of Existing Samples for Genome Research.GenetMed 2009;
11: 712–715; K.L. Edwards, A.A. Lemke, S.B. Trinidad, et al. Attitudes
Toward Genetic Research Review: Results from a Survey of Human
Genetics Researchers. Public health genomics 2011; 14: 337–345.
23 M.G. Hansson. Building on Relationships of Trust in Biobank
Research. J Med Ethics 2005; 31: 415–418; International Cancer
Genome Consortium. Goals, Structure, Policies and Guidelines 2008.
Available at: https://icgc.org/icgc/goals-structure-policies-guidelines
[Accessed 15 February 2014].
24 K.S. Steinsbekk & B. Solberg. Biobanks-When is Re-consent Neces-
sary? Public Health Ethics 2011; 4: 236–250.
25 Árnason op. cit. note 20; Bathe & McGuire op. cit. note 22; M.
DeCamp & J. Sugarman. Ethics in Behavioral Genetics Research.
Account Res 2004; 11: 27–47.
26 Z. Master, J.O. Claudio, C. Rachul, J.C. Wang, M.D. Minden & T.
Caulfield. Cancer Patient Perceptions on the Ethical and Legal Issues
Related to Biobanking. BMC Med Genomics 2013; 6: 8, p.1.
27 Trinidad et al., op. cit. note 20, p.3.
28 McCarty et al., op. cit. note 21; Bathe & McGuire, op. cit. note 22.
29 T.L. Beauchamp. Informed Consent: its History, Meaning, and
Present Challenges. Camb Q Healthc Ethics 2011; 20: 515–523.
30 L. Barnes, F.E. Matthews, B. Barber, L. Davies, D. Lloyd, C.
Brayne, et al. Brain Donation For Research: Consent and Re-Consent
Post Alder Hey. Bull Med Ethics 2005; 211: 17–21.
31 C. Cooper & R. Eeles. ICGC First Annual Report: Prostate Cancer
2013.
32 Steinsbekk & Solberg, op. cit. note 24, p.238.
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When considering major protocol changes, the term
‘major’ needs to be examined in terms of how it differs
from the original consent. The transfer of data and
samples into a database that can be accessed internation-
ally has raised questions, as this use might cause concerns
regarding the adequate protection of privacy and security
of data.33 One US project, the eMERGE (electronic
MEdical Records and Genomics) Network, funded by the
US National Institutes of Health (NIH), was required by
their IRB to re-consent participants in a longitudinal
cohort study included in its multi-institutional research
collaboration.34 This re-consent exercise was deemed as
required because NIH funded studies must deposit their
data into the federally-administrated database of Geno-
types and Phenotypes (dbGaP), an activity not covered in
the original Adult Changes in Thought (ACT) consent.
The re-consent exercise could be deemed successful
if the benchmark is a high rate of agreement: ‘of 1,340
cognitively intact study participants contacted for
re-consent, 1,159 (86%) agreed to participate in eMERGE
and have their data deposited in dbGaP; 152 (11%)
declined; and 29 (2%) were determined to be ineligible.’35
Adding a genetic component to an existing study is
generally agreed by commentators to be substantial
enough to warrant re-consent, as it raises issues of
re-identifiability and the potential impact on biological
relatives and social families who have not consented
directly and may have no understanding of the implica-
tions of participation.36 A survey of genetics researchers
and ethics review professionals found that the majority
believed that re-consent should also be sought when a
new gene variant was to be studied or genetic measures
added to a project.37 Researchers with HUNT 2 (the
Nord-Trøndelag Health Study) added a functional
genomics component to its long-running study, and con-
tacted 61,426 participants via post and other media to ask
for their consent.38 Only a small number of participants
(1.9% or 1,185) withdrew their consent.39 Re-consent was
sought by the international MONICA (Monitoring
trends and Determinants in Cardiovascular Disease)
project, in 2001, to ask permission to use existing blood
samples for ‘academic’ and ‘industrial’ genetic research.
Of the 1409 participants, 93% agreed to academic genetic
research and 91% agreed to industrial or commercial
genetic research.40
A further move is from the broad category of ‘genetic
research’ (e.g. the search for candidate genes) as pre-
sented to participants, to the more specific technology of
whole genome sequencing (WGS). Professionals appear
to see this as an increased risk to participants and are
more inclined to see whole genome methods as adding
extra complexity, given the potential for identifiability of
the data and for incidental findings.41 All ICGC member
studies are asked to obtain consent from their partici-
pants specifically for WGS; this is one of the core
bioethical elements that need to be respected by members
as a precondition of membership.42 Yet other commenta-
tors suggest that more advanced types of genetic research
may be carried out without re-consent if similar genetic
research was described in the original consent, as the
goals, risks and benefits may be similar and therefore
within the expectations of participants.43
Similarly, DeCamp and Sugarman suggest that
re-consent should occur before research into any topics
considered ‘controversial’, such as ‘violent behaviour’, as
it cannot be assumed that every participant would agree to
be involved.44 This obviously raises the question of what is
controversial. Commercial use has been cited as such,45 yet
the MRC Cognitive Function and Ageing Study discussed
earlier allowed respondents or their families to opt-out of
the use of samples by commercial companies, but very few
did,46 showing that commercial use was not, in this par-
ticular case, seen as controversial for all participants.
While one might assume that people would be risk-
adverse or have concerns, most participants in the studies
we found do agree to the new uses, even for what is
considered by many as a major or controversial change in
the protocol. The question can be asked whether profes-
sionals and others are seeing hypothetical dangers that
may not be troublesome for actual participants, or
whether participants actually need to be protected from
real dangers that they may not recognize or understand.
Another question is whether the act of asking is the cata-
lyst for acceptance, as individuals will decide differently
what is controversial, risky or concerning to them. There
33 Ludman et al., op. cit. note 3; E. Vermeulen, M.K. Schmidt, N.K.
Aaronson, M. Kuenen & F.E. van Leeuwen. Obtaining ‘Fresh’ Consent
for Genetic Research with Biological Samples Archived 10 Years Ago.
Eur J Cancer 2009; 45: 1168–1174.
34 Ludman et al., op. cit. note 3, p. 4.
35 Ibid: 4.
36 J. Holmen, K. Midthjell, Ø Krüger, A. Tverdal, T. Claudi, A.
Bjorndal, et al. The Nord-Trøndelag Health Study 1995–97 (HUNT 2):
Objectives, Contents, Methods and Participation. Norsk Epid 2003; 13:
19–32.
37 Edwards et al., op. cit. note 22.
38 Holmen et al., op. cit. note 36.
39 Ibid.
40 B. Stegmayr & K. Asplund. Informed Consent for Genetic Research
on Blood Stored for More Than a Decade: a Population Based Study.
BMJ 2002; 325: 634–635.
41 J. Kaye, P. Boddington, J. de Vries, N. Hawkins & K. Melham.
Ethical implications of the use of whole genome methods in medical
research. Eur J Hum Genet 2010; 18: 398–403.
42 International Cancer Genome Consortium, op. cit. note 23.
43 H.K. Tabor, T. Brazg, J. Crouch, E.E. Namey, S.M. Fullerton, L.M.
Beskow, et al. Parent Perspectives on Pediatric Genetic Research and
Implications For Genotype-Driven Research Recruitment. J Empir Res
Hum Res Ethics 2011; 6: 41–52.
44 DeCamp & Sugarman, op. cit. note 25, p.28.
45 Steinsbekk & Solberg, op. cit. note 24.
46 Barnes & Matthews, op. cit. note 30.
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is currently insufficient evidence to tease out the impact of
each of these on the many other factors on which a deci-
sion might rest.
Impact of re-consent and alternatives
Even if most agree, requesting re-consent can still have
an impact on studies, particularly when examined lon-
gitudinally. Figures provided by the MONICA study
show that it had lost 13% of its membership, primarily
through non-response or refusal by the end of its
re-consent exercise.47 Likewise, the ACT Study lost 14%
of its participants.48 Repeated re-consent will add to the
losses suffered. Putting in place a procedure and then
carrying out re-consent can be a costly choice; even if
only a very small number of people withdraw their
consent, one needs to ask when the cost is justified.49
To counter these concerns, alternatives have been sug-
gested. Anonymizing samples would negate the need for
re-consent and would enable data sharing, supporting
altruistic participation, but does not answer privacy fears
as anonymization is not a perfect protection and studies
have shown that individuals can be re-identified from
genetic datasets in certain circumstances.50 Anony-
mization also negates the ability to withdraw from a study
and should not be seen as a way to avoid ethical obliga-
tions to inform participants of any changes, participants
could still experience distress in cases where their
anonymized samples and data were used for reasons dif-
ferent from the ones to which they had consented.51
Using an opt-out system has been suggested where
re-contact is possible and the risks of the new research
were judged ‘minimal.’ Participants are notified by email,
post or regular newsletter and be given the chance to
opt-out of specific research uses or withdraw com-
pletely.52 However, this paradigm may not be acceptable
to participants. ACT participants overwhelmingly felt it
was important that they be asked (90%); a significant
minority (40%) did not agree with an opt-out paradigm.
Notification-only was even less popular (67% disagreed),
although the remaining third still found it acceptable
according to their understanding of their original
consent.53 This indicates the division of opinion and the
need for further research. In one UK study, the general
public suggested that their general practitioner (GP)
could act as an intermediary between them and research-
ers, when re-consent was sought.54 However, those sur-
veyed also acknowledged the inherent difficulties, such as
needing a stable relationship between researchers, partici-
pants and GPs, and the resource implications.55
The most common alternative being used is to make
the decision in conjunction with an oversight body,56 such
as an ethics committee.57 This aligns with a broad consent
model with governance structures to protect the interests
of participants. Ethics committees in countries such as
the US have the ability to provide a waiver for re-consent
if certain criteria are met.58 Publishers are another group
who act as decision-makers. The editors of PLOS Genet-
ics decided not to require 23andMe to re-consent 3000
research participants due to the perceived practical prob-
lems involved in contacting those individuals. The editors
did request that consent processes be amended in the
future59 and the company agreed.
Technological options, such as patient-centric initia-
tives, e.g. online interactive tools60 or dynamic consent
models,61 have also been suggested. Enabling participants
to review uses or agree to future research electronically
could ameliorate concerns over the burden or impact of
the re-consent process. It can support broad consent, if
the individual wishes to allow the study to make decisions
on their behalf, but it also gives participants the oppor-
tunity to choose the access level with which they are most
comfortable over time.62 Some authors believe that such a
system should routinely be incorporated into new longi-
tudinal studies.63
47 Stegmayr & Asplund, op. cit. note 40.
48 Ludman et al., op. cit. note 3.
49 L. Johnsson, M.G. Hansson, S. Eriksson & G. Helgesson. Patients’
Refusal to Consent to Storage and Use of Samples in Swedish
Biobanks: Cross Sectional Study. BMJ 2008; 337: 345.
50 E. Schadt, S. Woo & K. Hao. Bayesian Method to Predict Individual
SNP Genotypes from Gene Expression Data. Nat Genet 2012; 44: 603–
608.
51 D. Beyleveld & D. Townend. When is Personal Data Rendered
Anonymous? Interpreting Recital 26 of Directive 95/46/EC. Med Law
Int 2004; 6: 73–86.
52 D. Wendler & E. Emanuel. The Debate over Research on Stored
Biological Samples: What do Sources Think? Arch Intern Med 2002;
162: 1457–1462; G. Haddow, A. Bruce, S. Sathanandam, J.C. Wyatt.
‘Nothing is Really Safe’: a Focus Group Study on the Processes of
Anonymizing and Sharing of Health Data for Research Purposes. J
Eval Clin Pract 2010; 17: 1140–1146.
53 Ludman et al. op. cit. note 3.
54 Haddow et al. op. cit. note 52.
55 V. Armstrong, Wellcome Trust. Public Perspectives on the Govern-
ance to Biomedical Research: A Qualitative Study in a Deliberative
Context. Wellcome Trust; 2006.
56 T. Caulfield & B.M. Knoppers. Consent, Privacy & Research
Biobanks – Policy Brief No. 1. Genome Canada; 2010.
57 Steinsbekk & Solberg, op. cit. note 24; DeCamp & Sugarman, op. cit.
note 25.
58 Office for Human Research Protections op. cit. note 11.
59 G. Gibson & G.P. Copenhaver. Consent and Internet-Enabled
Human Genomics. PLoS Genet. 2010; 6.
60 N. Anderson & K. Edwards. Building a Chain of Trust: Using Policy
and Practice to Enhance Trustworthy Clinical Data Discovery and
Sharing. 2010.
61 J. Kaye, E.A. Whitley, D. Lund, M. Morrison, H. Teare & K.
Melham. Dynamic Consent: a Patient Interface for Twenty-First
Century Research Networks. Eur J Hum Genet 2014.
62 Anderson & Edwards, op. cit. note 60.
63 S.M. Fullerton, N.R. Anderson, G. Guzauskas, D. Freeman, K.
Fryer-Edwards. Meeting the Governance Challenges of Next-
Generation Biorepository Research. Science TranMed 2010; 2: 15cm13;
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However, technological options will not always be
appropriate, based on the difficulties of integrating them
into existing projects and only some participants will be
willing to engage on an individual level, which might affect
representativeness. More importantly, such options take
an individualistic stance on autonomy. This may not pay
due attention to those who wish to participate from a
position of solidarity, seeing participation as a public
good. A balance is needed between those who wish to take
an active part in decisions and those who are happy to let
the project make decisions on their behalf. Taking a
responsive autonomy approach would include discussions
with all parties about the current state of the project, its
future plans and what new issues it might face. It may help
us to judge the relative impacts of a perception of increased
risk, the pleasure in being asked, or annoyance in being
bothered on re-consent rates, leading to a more tailored
re-consent process. If communication is ongoing, and
there is a better understanding of the expectations and
needs of both participants and the project, re-consent may
not be required for every change in circumstance.
Challenges for re-consent
There are contradictory positions as to when changes
require re-consent. This is in part because those seeking
answers are approaching the question from different
angles with different stakeholders: the public who may
never participate in a research study, those who are cur-
rently being approached for participation, healthy volun-
teers and participants. These attitudes cannot easily be
reconciled; the public are answering hypothetical ques-
tions, while participants may be reacting from a position
of knowledge. Also, previous work has shown that par-
ticipants were generally more restrictive in their hypotheti-
calpreferences than in their actual response.64 Those in one
study were ‘perplexed by the need for re-consent, feeling
that they had already provided such consent in the original
wording.’65 This contrasts with studies where actual par-
ticipants and the public, in hypothetical situations, pre-
ferred re-consent for each new use.66 Actual participation
and proximity appear to influence a person’s perspective
towards the necessity for re-consent. Participants have
been shown to be happy to allow the project to make the
decision if there is belief and interest in the subject being
researched and trust in the project and its leaders.67
However, not all participants may be as trusting. Studies
examining this wider issue of trust between researchers
and participants have found similar diverging views.68
Professionals appear to be more cautious regarding
what should require re-consent as compared to the actual
evidence from re-consent exercises. New genetic method-
ologies are judged as needing re-consent by professionals,
yet when approached, a majority of participants say yes,
leading us to ask if participants see potential risks in a
different way or were reacting to the opportunity to state
a preference. In general, studies have shown that people
are quite happy with broad consent69 leading some par-
ticipants to wonder why researchers ‘are just not getting
on with the research.’70 Respecting the autonomy and
wishes of participants is difficult when there seems to be
no clear consensus across groups.
This calls into question what, in reality, we are trying
to protect or promote through re-consent. ‘Autonomy’,
or self-determination in the well-worn neo-liberal sense,
is the glib answer. But what type of autonomy is being
perpetuated in an approach to re-contact or re-consent a
research participant in the long-term projects interest us
here? We note, for example, that many of the justifica-
tions for re-approaching participants are driven by a lack
of knowledge or understanding about participants, or
better between participants and researchers. In many of
the re-consent scenarios discussed or envisioned in the
literature, participants are essentially passive; they are
cast as disempowered players on the research stage who
must be empowered with new knowledge and new
options. All of the responsibility for determining whether
re-consent should occur is placed on the researchers and
their governance mechanisms. The communication is uni-
directional, and not always welcome, as we have seen
above. This means that researchers and those who govern
them often have to second-guess participants’ perspec-
tives and how they themselves might view their own
autonomy. A common framework for such deliberations
is to ask: what would a reasonable or responsible partici-
pant need or want to know? But it is the participant alone
who is excluded from such musings. It removes the self-
from self-determination.
N. Anderson, C. Bragg, A. Hartzler & K. Edwards. Participant-Centric
Initiatives: Tools to Facilitate Engagement in Research. Appl Transl
Genomics 2012; 1: 25–29; C.M. Simon, J.K. Williams, L. Shinkunas, D.
Brandt, S. Daack-Hirsch & M. Driessnack. Informed Consent and
Genomic Incidental Findings: IRB Chair Perspectives. J Empir Res
Hum Res Ethics 2011; 6: 53–67.
64 J.M. Oliver, M.J. Slashinski, T. Wang, P.A. Kelly, S.G. Hilsenbeck &
A.L. McGuire. Balancing the Risks and Benefits of Genomic Data
Sharing: Genome Research Participants’ Perspectives. Public Health
Genomics 2012; 15: 106–114.
65 Barnes et al., op. cit. note 30, p. 19.
66 Murphy et al., op. cit. note 18; A. Tupasela, A. Sihvo, K. Snell, P.A.
Jallinoja, A.R. Aro, et al. Attitudes Towards Biomedical Use of Tissue
Sample Collections, Consent, and Biobanks Among Finns. Scand J
Public Health 2010; 38: 46–52; Master et al., op. cit. note 26; C.M.
Halverson & L.F. Ross. Incidental Findings of Therapeutic Misconcep-
tion in Biobank-Based Research. Genet Med 2012; 14(6): 611–615.
67 Master et al., op. cit. note 26.
68 M. Dixon-Woods, R.E. Ashcroft, C.J. Jackson, et al. Beyond ‘Mis-
understanding’: Written Information and Decisions about Taking Part
in a Genetic Epidemiology Study. Soc Sci Med 2007; 65: 2212–2222.
69 Armstrong & Wellcome Trust, op. cit. note 55; Simon et al. op. cit.
note 63.
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Equally, the retort cannot be: ‘just ask’, because this
would require approaches in the case of all new uses, and
this is neither necessary nor proportionate, nor ironically,
would it promote autonomy in all cases (since some
people would resent the approach). We suggest that what
is required in these cases is a genuine sharing of informa-
tion and power in the relationship throughout its course,
and from the participant’s perspective there should be
more promotion of the concept of ‘responsive
autonomy’. For us, this embraces the idea that with
autonomy comes responsibility. In this context, it would
be a responsibility for researchers to engage actively with
the participant community about options and proposals,
e.g. through a study website or newsletter. For partici-
pants it would be a responsibility to engage in this
process, providing feedback and comment on said
options and proposals. Responsive autonomy would
promote a dialogue between researchers about the aims
of the study and the future of the science, with partici-
pants who can discuss their understandings and expecta-
tions. Such discussions could help make clearer the bases
on which decisions on re-consent are made. Open and
on-going two-way communication, as part of a respon-
sive autonomy approach, on issues that might be ground-
breaking and therefore unknown and potentially ‘scary’
might help to disabuse concerns and pre-empt the need
for re-consent.
CONCLUSION
The shifting nature of science highlights the ever-present
struggle to balance the pursuit of research outcomes with
participants’ rights to make autonomous decisions about
research uses of their data and samples. It is a challenge
to balance the desire for control with the desire to see
research progress; it is a greater challenge when the
public, participants, patients and experts hold different
opinions and no consensus can be reached.
Our study is limited in that there are insufficient studies
with each of these groups in order to clearly define when
and for what reasons re-consent should be undertaken.
We advocate the continued collection of evidence from
re-consent exercises and recommend the development of
best practice guidelines. Also, most of the projects dis-
cussed were conducted in the UK and the US and we
would welcome more evidence from other groups inter-
nationally, as these will reflect different cultural perspec-
tives towards the issues. At this time we risk making
judgements that cannot be generalized across countries.
In summary, some points are clear. Re-consent policies
need to be considered when a project is designed and part
of the original consent. The original consent must be seen
as setting a baseline of the expectations of both the par-
ticipant and the project, and a benchmark against which
future re-consent decisions are based. Consent is an
ongoing responsive process of communication, showing
respect for autonomy and is not a series of yes or no
answers. Re-consent may be minimized if this is borne in
mind throughout the project. Consent is not, on the other
hand, the same as respect for autonomy. Participants
should be able to opt-out of projects if they wish; equally
they should be able to consent and leave the future deci-
sions to others. There is a clear recognition by the public
and participants that re-consent can be onerous, but they
still see the value in being asked. Whether this can ever be
reconciled is unknown but needs to be explored.
When change occurs, re-consent can show respect to
participants, as well as, ‘to the institution of consent’.71
But attention also needs to be paid to the desire shown by
people to contribute to research and to the scientific
studies seeking to improve people’s lives and health. A
‘happy medium’ is needed.
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